Cargando…

Rituximab as Initial Therapy in Adult Patients With Minimal Change Disease

Detalles Bibliográficos
Autores principales:	Guan, Nan, Zhang, Min, Chen, Ruiying, Xie, Qionghong, Hao, Chuan-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166732/ https://www.ncbi.nlm.nih.gov/pubmed/37180513 http://dx.doi.org/10.1016/j.ekir.2023.02.1070

Ejemplares similares

Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis
por: Ren, Hong, et al.
Publicado: (2017)

The efficacy of rituximab in adult frequently relapsing minimal change disease
por: King, Catherine, et al.
Publicado: (2017)

Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients
por: Shang, Da, et al.
Publicado: (2017)

Rituximab for Steroid-Dependent Minimal Change Disease in Adults: Is It Time for a Change?
por: Kannan, Lakshmi
Publicado: (2022)

Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome
por: Fenoglio, Roberta, et al.
Publicado: (2018)

Minimization of administration route errors with subcutaneous rituximab
por: Liptrott, Sarah, et al.
Publicado: (2016)

Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis
por: Hansrivijit, Panupong, et al.
Publicado: (2020)

Efficacy of low-dose rituximab in minimal change disease and prevention of relapse
por: Zhang, Jian, et al.
Publicado: (2023)

Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis
por: Lin, Li, et al.
Publicado: (2021)

Matrix protein Tenascin-C promotes kidney fibrosis via STAT3 activation in response to tubular injury
por: Xie, Qionghong, et al.
Publicado: (2022)

Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies
por: Madanchi, Nima, et al.
Publicado: (2017)

Efficacy of rituximab in thymoma associated minimal change disease: case report
por: El Ouafi, Zhour, et al.
Publicado: (2021)

Rheumatoid arthritis with aquaporin-4 antibody-positive neuromyelitis optica receiving rituximab therapy
por: Reen Wang, Chrong, et al.
Publicado: (2021)

Review of the Role of Rituximab in the Management of Adult Minimal Change Disease and Immune-Mediated Focal and Segmental Glomerulosclerosis
por: Aslam, Ahsan, et al.
Publicado: (2023)

Elevated Serum Tenascin-C Predicts Mortality in Critically Ill Patients With Multiple Organ Dysfunction
por: Xu, Yunyu, et al.
Publicado: (2021)

Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease
por: Papakrivopoulou, Eugenia, et al.
Publicado: (2016)

Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
por: Buchegger, Franz, et al.
Publicado: (2011)

Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease
por: Liu, Diankun, et al.
Publicado: (2021)

Sustained complete remission of steroid- and cyclophosphamide-resistant minimal-change disease with a single course of rituximab therapy
por: Janardan, Jyotsna, et al.
Publicado: (2014)

Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease
por: Iwabuchi, Yuko, et al.
Publicado: (2018)

Rituximab-induced pneumonitis mimicking miliary tuberculosis
por: Yao, Chih-Wei, et al.
Publicado: (2013)

Calcineurin B1 subunit in human peripheral blood mononuclear cells and its role in idiopathic membranous nephropathy
por: Zhu, Ying, et al.
Publicado: (2019)

Efficacy and safety of tacrolimus versus corticosteroid as initial monotherapy in adult-onset minimal change disease: a meta-analysis
por: Lu, Jingkui, et al.
Publicado: (2022)

Membranous nephropathy in a patient with ankylosing spondylitis: A case report
por: Chen, Ruiying, et al.
Publicado: (2017)

Minimal Change Disease Associated With Durvalumab
por: Toda, Masataro G., et al.
Publicado: (2021)

Post-vaccinal minimal change disease
por: Weijers, Jari, et al.
Publicado: (2021)

Interstitial pneumonitis related to rituximab therapy for Waldenström's macroglobulinemia
por: Bai, Xueyan, et al.
Publicado: (2015)

Kimura Disease Associated with Minimal Change Disease
por: Eren, Rafet, et al.
Publicado: (2021)

A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia
por: Ma, Wanlu, et al.
Publicado: (2021)

Successful Treatment of New-Onset Pediatric Nephrotic Syndrome With Rituximab as a First-Line Therapy
por: Zhang, Xiaojing, et al.
Publicado: (2022)

Long-Term Prognosis of Adult Patients with Steroid-Dependent Minimal Change Nephrotic Syndrome Following Rituximab Treatment
por: Iwabuchi, Yuko, et al.
Publicado: (2014)

Favorable outcome in PLA2R positive HBV-associated membranous nephropathy
por: Chen, Ruiying, et al.
Publicado: (2022)

Case report: Successful outcome of treatment using rituximab in an adult patient with refractory minimal change disease and β-thalassemia complicating autoimmune hemolytic anemia
por: Zhuang, Jing, et al.
Publicado: (2022)

Steroid Minimization in Adults with Minimal Change Disease
por: Koirala, Abbal, et al.
Publicado: (2021)

Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis
por: Xue, Cheng, et al.
Publicado: (2020)

Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells
por: Webendörfer, Maximilian, et al.
Publicado: (2021)

The use of tacrolimus in the management of minimal change disease
Publicado: (2012)

Rituximab-containing therapy for cold agglutinin disease: a retrospective study of 16 patients
por: Jia, Ming-nan, et al.
Publicado: (2020)

A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood
por: Dekkers, Marinus J, et al.
Publicado: (2015)

Spontaneous Bacterial Peritonitis in an Adult Patient with Minimal Change Disease
por: Lee, In Hee, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2hvokalbt8e8dfr1smd5lq8cqt